Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(4)
•••
Comment by HossBenderon Jan 30, 2018 12:38am
107 Views
Post# 27460076

RE:New MD&A and other sedar

RE:New MD&A and other sedar "Within the xB3 program, management intends to advance preclinical development of the xB3-TZM program (001 in Brain Metastasis), key development milestones and current target dates for completion (calendar year) include: initiation of manufacturing (Q1 of 2018), request FDA Type B (pre-IND) meeting (Q3 of 2018), initiation of toxicology program (Q2 of 2019) and begin our first-in-man Ph 1 /2 clinical study (Q4 of 2019). The company also intends to fund further work on its other preclinical pipeline programs: the 002 program in Glioblastoma, the company plans to complete preclinical proof-of-concept (POC) (Q3 of 2018), initiate manufacturing (Q4 of 2018) and initiate toxicology studies (Q4 of 2019). For the 007 program in neurodegeneration, the company will plan to complete preclinical POC (Q4 of 2018) and initiate manufacturing (Q1 of 2019)."

Looks like 2020 might be the year for BTI. 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities